Publications
2025
ABS0444 MEDICATION ADHERENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS: INSIGHTS FROM A KENYAN SLE COHORT (KESLER)
Achieng, S., Bruce, I., Turtle, L., & Oyoo, G. (2025). ABS0444 MEDICATION ADHERENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS: INSIGHTS FROM A KENYAN SLE COHORT (KESLER). Annals of the Rheumatic Diseases, 84, 2204. doi:10.1016/j.ard.2025.06.1847
LONG-TERM INFECTION RISK IN MODERATE-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP BIOLOGICS REGISTER (BILAG-BR): A PROSPECTIVE LONGITUDINAL STUDY
Achieng, S., Dyball, S., Rodziewicz, M., Sutton, E., Parker, B., Wootton, D., . . . Bruce, I. (2025). LONG-TERM INFECTION RISK IN MODERATE-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP BIOLOGICS REGISTER (BILAG-BR): A PROSPECTIVE LONGITUDINAL STUDY. The Journal of Rheumatology, 52(Suppl 1), 65-66. doi:10.3899/jrheum.2025-0390.pt003
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. (2025). Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.. The Lancet. Infectious diseases, S1473-3099(25)00093-3. doi:10.1016/s1473-3099(25)00093-3
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. (2025). Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.. EClinicalMedicine, 81, 103080. doi:10.1016/j.eclinm.2025.103080
2024
An imperfect world: assessing safety of biological treatments in systemic lupus erythematosus. Comment on the article by Materne et al.
Rodziewicz, M., Dyball, S., Achieng, S., Brix, S. R., Parker, B., & Bruce, I. N. (2024). An imperfect world: assessing safety of biological treatments in systemic lupus erythematosus. Comment on the article by Materne et al.. Arthritis & rheumatology (Hoboken, N.J.), 76(2), 315-316. doi:10.1002/art.42689
2023
A rare form of calcinosis in patients with systemic sclerosis-myositis overlap: report of four cases.
Achieng, S., Harris, J., Samaranayaka, M., & Herrick, A. L. (2024). A rare form of calcinosis in patients with systemic sclerosis-myositis overlap: report of four cases.. Rheumatology advances in practice, 8(1), rkae011. doi:10.1093/rap/rkae011
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. (2023). Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.. The lancet. Diabetes & endocrinology, S2213-8587(23)00253-X. doi:10.1016/s2213-8587(23)00253-x
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Horby, P. W., Emberson, J. R., Basnyat, B., Campbell, M., Peto, L., Pessoa-Amorim, G., . . . Landray, M. J. (2023). Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. LANCET, 401(10387), 1499-1507. doi:10.1016/S0140-6736(23)00510-X
2022
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Horby, P. W., Emberson, J. R., Mafham, M., Campbell, M., Peto, L., Pessoa-Amorim, G., . . . Landray, M. J. (2022). Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. LANCET, 400(10349), 359-368. Retrieved from https://www.webofscience.com/
OA41 Audit of the rheumatology PIFU pathway at the UHMB Trust
Achieng, S., Gray, L., & Ottewell, L. (2022). OA41 Audit of the rheumatology PIFU pathway at the UHMB Trust. Rheumatology, 61(Supplement_1). doi:10.1093/rheumatology/keac132.041
2021
P170 The validity and utility of the SLE-key® rule-out serological test when applied in a selected cohort of patients with SLE and other connective tissue diseases
Achieng, S., Reynolds, J. A., Bruce, I. N., & Bukhari, M. (2021). P170 The validity and utility of the SLE-key® rule-out serological test when applied in a selected cohort of patients with SLE and other connective tissue diseases. Rheumatology, 60(Supplement_1). doi:10.1093/rheumatology/keab247.165
Bamboo nodes of the vocal cords: an often-overlooked cause of dysphonia in autoimmune disease.
Sheilla, A., & Surabhi, W. (2021). Bamboo nodes of the vocal cords: an often-overlooked cause of dysphonia in autoimmune disease.. Rheumatology (Oxford, England), 60(4), 1973. doi:10.1093/rheumatology/keaa570